

NCT03026088 Raw comparison:

Summary:
CHIA has 50 criteria while your personal folder has 52 criteria
Total found criteria: 50/50
Total not Found: 0/50
Total Extra: 2
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ 18-80 year male or female                          │ 18-80 year male or female                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Chronic Heart failure subjects with medical        │ Chronic Heart failure subjects with medical        │
│ history of cardiac disease or other related        │ history of cardiac disease or other related        │
│ cardiovascular disease                             │ cardiovascular disease                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Left ventricular ejection fraction (LVEF) less     │ Left ventricular ejection fraction (LVEF) less     │
│ than or equal to (=<) 40 percent (%)               │ than or equal to (=\<) 40 percent (%)              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ New York Heart Association (NYHA) class of II - IV │ New York Heart Association (NYHA) class of II - IV │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ NYHA II Slight limitation of physical activity     │ NYHA II ： Slight limitation of physical activity  │
│ Comfortable at rest but ordinary physical activity │ Comfortable at rest but ordinary physical activity │
│ results in undue breathlessness fatigue or         │ results in undue breathlessness fatigue or         │
│ palpitation                                        │ palpitation                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ NYHA III Marked limitation of physical activity    │ NYHA III：Marked limitation of physical activity   │
│ Comfortable at rest but less than ordinary         │ Comfortable at rest but less than ordinary         │
│ activity causes undue breathlessness fatigue or    │ activity causes undue breathlessness fatigue or    │
│ palpitation                                        │ palpitation                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ NYHA IV Unable to carry on any physical activity   │ NYHA IV：Unable to carry on any physical activity  │
│ without discomfort Symptoms at rest can be present │ without discomfort Symptoms at rest can be present │
│ If any physical activity is undertaken discomfort  │ If any physical activity is undertaken discomfort  │
│ increased                                          │ increased                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Signed Informed Consent Form (ICF)                 │ Signed Informed Consent Form (ICF)                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Acute coronary syndrome (ACS) within 3 months      │ Acute coronary syndrome (ACS) within 3 months      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Under beta-blocker treatment for the last 2 weeks  │ Under beta-blocker treatment for the last 2 weeks  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Under other medicine treatment which may affect    │ Under other medicine treatment which may affect    │
│ heart rate like Non-dihydropyridine calcium        │ heart rate like Non-dihydropyridine calcium        │
│ channel blockers (NDHP-CCBs) or ivabradine for the │ channel blockers (NDHP-CCBs) or ivabradine for the │
│ last 2 weeks Under Digoxin treatment [more than    │ last 2 weeks Under Digoxin treatment \[more than   │
│ (>) 0 125 milligram (mg)]                          │ (\>) 0 125 milligram (mg)\]                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Uncontrolled Diabetes [hemoglobin A1c (HbA1c) >7   │ Uncontrolled Diabetes \[hemoglobin A1c (HbA1c) \>7 │
│ 5%]                                                │ 5%\]                                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Severe or uncontrolled hypertension [resting       │ Severe or uncontrolled hypertension \[resting      │
│ Systolic Blood Pressure (SBP) >180 millimeters of  │ Systolic Blood Pressure (SBP) \>180 millimeters of │
│ mercury (mmHg) or resting Diastolic Blood Pressure │ mercury (mmHg) or resting Diastolic Blood Pressure │
│ (DBP) >110mmHg at screening period]                │ (DBP) \>110mmHg at screening period\]              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Severe hypotension [resting SBP less than (<)      │ Severe hypotension \[resting SBP less than (\<)    │
│ 90mmHg or resting DBP<50mmHg]                      │ 90mmHg or resting DBP\<50mmHg\]                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Resting heart rate <60 beat per minute (bpm)       │ Resting heart rate \<60 beat per minute (bpm)      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any contradiction to Bisoprolol according to label │ Any contradiction to Bisoprolol according to label │
│ including                                          │ including                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Acute heart failure or during episodes of heart    │ Acute heart failure or during episodes of heart    │
│ failure decompensation requiring intravenous       │ failure decompensation requiring intravenous       │
│ inotropic therapy                                  │ inotropic therapy                                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Cardiogenic shock                                  │ Cardiogenic shock                                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Atrioventricular block of second or third degree   │ Atrioventricular block of second or third degree   │
│ (without a pacemaker)                              │ (without a pacemaker)                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Sick sinus syndrome                                │ Sick sinus syndrome                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Sinoatrial block                                   │ Sinoatrial block                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Slowed heart rate causing symptoms (symptomatic    │ Slowed heart rate causing symptoms (symptomatic    │
│ bradycardia)                                       │ bradycardia)                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Decreased blood pressure causing symptoms          │ Decreased blood pressure causing symptoms          │
│ (symptomatic hypotension)                          │ (symptomatic hypotension)                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Severe bronchial asthma or severe chronic          │ Severe bronchial asthma or severe chronic          │
│ obstructive pulmonary disease                      │ obstructive pulmonary disease                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Sever forms of peripheral arterial occlusive       │ Sever forms of peripheral arterial occlusive       │
│ disease and Raynaud's syndrome                     │ disease and Raynaud's syndrome                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Untreated phaeochromocytoma                        │ Untreated phaeochromocytoma                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Metabolic acidosis                                 │ Metabolic acidosis                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Hypersensitivity to bisoprolol or to any of the    │ Hypersensitivity to bisoprolol or to any of the    │
│ excipients                                         │ excipients                                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Severe Arrhythmia including atrial fibrillation    │ Severe Arrhythmia including atrial fibrillation    │
│ atrial flutter ventricular fibrillation            │ atrial flutter ventricular fibrillation            │
│ ventricular flutter or ventricular tachycardia     │ ventricular flutter or ventricular tachycardia     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Significant valvular heart disease congenital      │ Significant valvular heart disease congenital      │
│ heart disease pulmonary heart disease or perinatal │ heart disease pulmonary heart disease or perinatal │
│ heart disease                                      │ heart disease                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Acute pulmonary edema                              │ Acute pulmonary edema                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Severe hepatic dysfunction defined as              │ Severe hepatic dysfunction defined as              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Serum Alanine Aminotransferase (ALT) > triple the  │ Serum Alanine Aminotransferase (ALT) \> triple the │
│ upper limit of the normal range and/or             │ upper limit of the normal range and/or             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Serum Aspartate Aminotransferase (AST) > triple    │ Serum Aspartate Aminotransferase (AST) \> triple   │
│ the upper limit of the normal value range and/or   │ the upper limit of the normal value range and/or   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Severe renal dysfunction defined as                │ Severe renal dysfunction defined as                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Serum creatinine > twice the upper limit of the    │ Serum creatinine \> twice the upper limit of the   │
│ normal range                                       │ normal range                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Chronic Kidney Disease (glomerular filtration rate │ Chronic Kidney Disease (glomerular filtration rate │
│ <45 Milliliter per minute)                         │ \<45 Milliliter per minute)                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Hyperthyroidism or hypothyroidism                  │ Hyperthyroidism or hypothyroidism                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Severe infectious disease example (eg) Human       │ Severe infectious disease example (eg) Human       │
│ Immunodeficiency Virus positive or active          │ Immunodeficiency Virus positive or active          │
│ tuberculosis                                       │ tuberculosis                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Severe autoimmune disease e g lupus erythematosus  │ Severe autoimmune disease e g lupus erythematosus  │
│ multiple sclerosis                                 │ multiple sclerosis                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Severe respiratory digestive hematological disease │ Severe respiratory digestive hematological disease │
│ (including Anemia of Hb < 100 gram per litre) or   │ (including Anemia of Hb \< 100 gram per litre) or  │
│ tumor                                              │ tumor                                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Known to be hypersensitivity to Bisoprolol or any  │ Known to be hypersensitivity to Bisoprolol or any  │
│ of the excipient                                   │ of the excipient                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Substance or alcohol abuse                         │ Substance or alcohol abuse                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Received heart transplantation or pacemaker        │ Received heart transplantation or pacemaker        │
│ implantation revascularization treatment within 3  │ implantation revascularization treatment within 3  │
│ months or plan to receive above treatment in 6     │ months or plan to receive above treatment in 6     │
│ months                                             │ months                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Currently undertaking other treatment that may     │ Currently undertaking other treatment that may     │
│ affect the safety and/or efficacy evaluation e g   │ affect the safety and/or efficacy evaluation e g   │
│ beta receptors agonists et cetera                  │ beta receptors agonists et cetera                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ No legal ability or legal ability is limited       │ No legal ability or legal ability is limited       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects unlikely to cooperate in the study or     │ Subjects unlikely to cooperate in the study or     │
│ with inability or unwillingness to give informed   │ with inability or unwillingness to give informed   │
│ consent                                            │ consent                                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Child-bearing period women without effective       │ Child-bearing period women without effective       │
│ contraceptive measures pregnancy and lactation     │ contraceptive measures pregnancy and lactation     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Participation in another clinical trial within the │ Participation in another clinical trial within the │
│ past 90 days                                       │ past 90 days                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Other significant condition that in the            │ Other significant condition that in the            │
│ Investigator's opinion would exclude the subject   │ Investigator's opinion would exclude the subject   │
│ from the trial                                     │ from the trial                                     │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒═══════════════════════════════════╕
│ Extra Personal Criteria           │
╞═══════════════════════════════════╡
│ Must have maximum age of 80 Years │
├───────────────────────────────────┤
│ Must have minimum age of 18 Years │
╘═══════════════════════════════════╛